Fenbufen
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328906

CAS#: 36330-85-5

Description: Fenbufen, also known as Cinopal and CL-82204, is an arylpropionic acid derivative belonging to the group of non-steroidal anti-inflammatory drugs.


Price and Availability

Size
Price

5g
USD 230
Size
Price

10g
USD 390
Size
Price

Fenbufen (Cinopal, Lederfen, CL-82204) purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 328906
Name: Fenbufen
CAS#: 36330-85-5
Chemical Formula: C16H14O3
Exact Mass: 254.0943
Molecular Weight: 254.285
Elemental Analysis: C, 75.58; H, 5.55; O, 18.88


Synonym: Fenbufen; Cinopal; Lederfen; CL-82204; CL 82204; CL82204

IUPAC/Chemical Name: 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid

InChi Key: ZPAKPRAICRBAOD-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)

SMILES Code: O=C(O)CCC(C1=CC=C(C2=CC=CC=C2)C=C1)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Syed M, Skonberg C, Hansen SH. Inhibition of ATP synthesis by fenbufen and its conjugated metabolites in rat liver mitochondria. Toxicol In Vitro. 2016 Mar;31:23-9. doi: 10.1016/j.tiv.2015.11.013. Epub 2015 Nov 21. PubMed PMID: 26612354.

2: Ferrone V, Carlucci M, Palumbo P, Carlucci G. Bioanalytical method development for quantification of ulifloxacin, fenbufen and felbinac in rat plasma by solid-phase extraction (SPE) and HPLC with PDA detection. J Pharm Biomed Anal. 2016 May 10;123:205-12. doi: 10.1016/j.jpba.2016.01.062. Epub 2016 Feb 1. PubMed PMID: 26898973.

3: Dhaneshwar S, Kusurkar M, Bodhankar S, Bihani G. Carrier-linked mutual prodrugs of biphenylacetic acid as a promising alternative to bioprecursor fenbufen: design, kinetics, and pharmacological studies. Inflammopharmacology. 2014 Aug;22(4):235-50. doi: 10.1007/s10787-013-0194-4. Epub 2013 Nov 1. PubMed PMID: 24178955.

4: Huang YC, Chang YC, Yeh CN, Yu CS. Synthesis and Biological Evaluation of an (18)Fluorine-Labeled COX Inhibitor--[(18)F]Fluorooctyl Fenbufen Amide--For Imaging of Brain Tumors. Molecules. 2016 Mar 21;21(3):387. doi: 10.3390/molecules21030387. PubMed PMID: 27007363.

5: Yang Y, Gao H. Density functional theory study on the molecular structure and vibration spectra of fenbufen. Spectrochim Acta A Mol Biomol Spectrosc. 2013 Jan 15;101:119-26. doi: 10.1016/j.saa.2012.09.034. Epub 2012 Sep 26. PubMed PMID: 23099169.

6: Huang HL, Yeh CN, Lee WY, Huang YC, Chang KW, Lin KJ, Tien SF, Su WC, Yang CH, Chen JT, Lin WJ, Fan SS, Yu CS. [123I]Iodooctyl fenbufen amide as a SPECT tracer for imaging tumors that over-express COX enzymes. Biomaterials. 2013 Apr;34(13):3355-65. doi: 10.1016/j.biomaterials.2013.01.050. Epub 2013 Feb 4. PubMed PMID: 23384791.

7: Lin KI, Yang CH, Huang CW, Jian JY, Huang YC, Yu CS. Synthesis and structure-activity relationships of fenbufen amide analogs. Molecules. 2010 Dec 2;15(12):8796-803. doi: 10.3390/molecules15128796. PubMed PMID: 21127465.

8: Su YH, Chiang LW, Jeng KC, Huang HL, Chen JT, Lin WJ, Huang CW, Yu CS. Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1320-4. doi: 10.1016/j.bmcl.2011.01.068. Epub 2011 Jan 22. PubMed PMID: 21315586.

9: Carriazo D, del Arco M, Fernández A, Martín C, Rives V. Inclusion and release of fenbufen in mesoporous silica. J Pharm Sci. 2010 Aug;99(8):3372-80. doi: 10.1002/jps.22096. PubMed PMID: 20232455.

10: De Sarro G, Renne S, Nava F, De Sarro A. Fenbufen pretreatment potentiates the anticonvulsant activity of CPPene and NBQX in DBA/2 mice. J Pharm Pharmacol. 1994 Dec;46(12):1017-22. PubMed PMID: 7714713.

11: Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K. Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. J Pharmacol Exp Ther. 1991 Sep;258(3):1033-7. PubMed PMID: 1890610.

12: Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K. A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats. J Pharmacobiodyn. 1990 Feb;13(2):90-6. PubMed PMID: 2384853.

13: Crossley RJ. Side effect and safety data for fenbufen. Am J Med. 1983 Oct 31;75(4B):84-90. PubMed PMID: 6227235.

14: Chiccarelli FS, Eisner HJ, Van Lear GE. Disposition and metabolism of fenbufen in several laboratory animals. Arzneimittelforschung. 1980;30(4A):707-15. PubMed PMID: 6776965.

15: Moore RA, Derry S, McQuay HJ. Single dose oral fenbufen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007547. doi: 10.1002/14651858.CD007547.pub2. Review. PubMed PMID: 19821427; PubMed Central PMCID: PMC4175557.